Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthijs L Becker

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Pharmacogenetics and Genomics|November 10, 2009
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin responseMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Cardiovascular Toxicology|January 2, 2021
QTc Prolongation in COVID-19 Patients Using ChloroquineMatthijs L Becker, Dominic Snijders, Claudia W van Gemeren, et al.
Pharmacoepidemiology and Drug Safety|October 6, 2009
Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapyMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Diabetes|February 21, 2009
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary studyMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Neurogenetics|August 4, 2010
OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug usersMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Pharmacogenomics|November 7, 2009
Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in malesMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Pharmacoepidemiology and Drug Safety|December 13, 2006
Hospitalisations and emergency department visits due to drug-drug interactions: a literature reviewMatthijs L Becker, Marjon Kallewaard, Peter W J Caspers, et al.
Pharmacogenetics and Genomics|January 21, 2015
The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levelsCatherine E de Keyser, Matthijs L Becker, Albert Hofman, et al.
International Journal of Clinical Pharmacy|September 30, 2020
The effect of medication related clinical decision support at the time of physician order entryMatthijs L Becker, Fatih Baypinar, Marieke Pereboom, et al.
Therapeutic Advances in Gastroenterology|September 14, 2023
Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilarRosanne W Meijboom, Helga Gardarsdottir, Matthijs L Becker, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Pharmacogenetics and Genomics|November 10, 2009
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin responseMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Cardiovascular Toxicology|January 2, 2021
QTc Prolongation in COVID-19 Patients Using ChloroquineMatthijs L Becker, Dominic Snijders, Claudia W van Gemeren, et al.
Pharmacoepidemiology and Drug Safety|October 6, 2009
Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapyMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Diabetes|February 21, 2009
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary studyMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Neurogenetics|August 4, 2010
OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug usersMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Pharmacogenomics|November 7, 2009
Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in malesMatthijs L Becker, Loes E Visser, Ron H N van Schaik, et al.
Pharmacoepidemiology and Drug Safety|December 13, 2006
Hospitalisations and emergency department visits due to drug-drug interactions: a literature reviewMatthijs L Becker, Marjon Kallewaard, Peter W J Caspers, et al.
Pharmacogenetics and Genomics|January 21, 2015
The rs13064411 polymorphism in the WDR52 gene, associated with PCSK9 levels, modifies statin-induced changes in serum total and LDL cholesterol levelsCatherine E de Keyser, Matthijs L Becker, Albert Hofman, et al.
International Journal of Clinical Pharmacy|September 30, 2020
The effect of medication related clinical decision support at the time of physician order entryMatthijs L Becker, Fatih Baypinar, Marieke Pereboom, et al.
Therapeutic Advances in Gastroenterology|September 14, 2023
Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilarRosanne W Meijboom, Helga Gardarsdottir, Matthijs L Becker, et al.
Pageof 5